Cited by 764Cancer-related Molecular PathwaysMultiple and Secondary Primary CancersBRCA gene mutations in cancer

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Bougeard, Gaëlle, Renaux-Petel, Mariette, Flaman, Jean-Michel, Charbonnier, Camille, Fermey, Pierre, Belotti, Muriel, Gauthier-Villars, Marion, Stoppa-Lyonnet, Dominique, Consolino, Emilie, Brugières, Laurence, Caron, Olivier, Benusiglio, Patrick R., Bressac-de Paillerets, Brigitte, Bonadona, Valérie, Bonaïti-Pellié, Catherine, Tinat, Julie, Baert-Desurmont, Stéphanie, Frebourg, Thierry·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.5728

Open this paper in CoChat — free account

Abstract

Purpose: The aim of the study was to update the description of Li-Fraumeni syndrome (LFS), a remarkable cancer predisposition characterized by extensive clinical heterogeneity. Patients and Methods: From 1,730 French patients suggestive of LFS, we identified 415 mutation carriers in 214 families harboring 133 distinct TP53 alterations and updated their clinical presentation. Results: The 322 affected carriers developed 552 tumors, and 43% had developed multiple malignancies. The mean age of first tumor onset was 24.9 years, 41% having developed a tumor by age 18. In childhood, the LFS tumor spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults, the tumor distribution was characterized by the predominance of breast carcinomas observed in 79% of the females, and STS observed in 27% of the patients. The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and in females with breast cancer before age 31 years, without additional features indicative of LFS, was 45%, 42% and 6%, respectively. The mean age of tumor onset was statistically different (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC, harbored mostly dominant-negative missense mutations. Conclusion: The clinical gradient of the germline TP53 mutations, which should be validated by other studies, suggests that it might be appropriate to stratify the clinical management of LFS according to the class of the mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.5728

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“Dominant-negative mutations were defined on the basis of the ability of the mutant protein to inhibit the activity of the wild-type p53 protein,(16) as indicated in the International Agency for Research on Cancer TP53 Database.(17)”
Method
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 553

Show all 42 references

Research works printed but not linked: 3

Li FP, 1988, Cancer Res, 48, 5358
Nutting C, 2000, Clin Oncol (R Coll Radiol), 12, 300
Spencer SJ, 1999, J Clin Endocrinol Metab, 84, 1110

Sorted by citations

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A. M., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,143
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study
Villani, A., Shore, A., Wasserman, J. D., Stephens, D., Kim, R. H., Druker, H., Gallinger, B., Naumer, A., Kohlmann, W., Novokmet, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30249-2 · Cited by 546
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
Kratz, C. P., Achatz, M. I., Brugières, L., Frebourg, T., Garber, J. E., Greer, M.-L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0408 · Cited by 534
Self-citation
Lung cancer statistics, 2023
Kratzer, T. B., Bandi, P., Freedman, N. D., Smith, R. A., Travis, W. D., Jemal, A., & Siegel, R. L. (2024) · Cancer · doi:10.1002/cncr.35128 · Cited by 570
Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort
Mai, P. L., Best, A. F., Peters, J. A., DeCastro, R. M., Khincha, P. P., Loud, J. T., Bremer, R. C., Rosenberg, P. S., & Savage, S. A. (2016) · Cancer · doi:10.1002/cncr.30248 · Cited by 487
Review of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 409
Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes
The European Reference Network GENTURIS, Frébourg, T., Bajalica‐Lagercrantz, S., Oliveíra, C., Mágenheim, R., & Evans, D. G. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-0638-4 · Cited by 358
Somatic TP53 Mutations in the Era of Genome SequencingPreprint
Hainaut, P. L., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 256
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing
Newman, S., Nakitandwe, J., Kesserwan, C. A., Azzato, E. M., Wheeler, D. A., Rusch, M., Shurtleff, S. A., Hedges, D. J., Hamilton, K. V., Foy, S. G., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1631 · Cited by 226
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Ballinger, M. L., Goode, D. L., Ray-Coquard, I. L., James, P. A., Mitchell, G., Niedermayr, E., Puri, A., Schiffman, J. D., Dite, G. S., Cipponi, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30147-4 · Cited by 223
Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging
Ballinger, M. L., Best, A. F., Mai, P. L., Khincha, P. P., Loud, J. T., Peters, J. A., Achatz, M. I., Chojniak, R., da Costa, A. A. B. A., Santiago, K. M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1968 · Cited by 198
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 208
Tumour predisposition and cancer syndromes as models to study gene–environment interactions
Carbone, M., Arron, S. T., Beutler, B., Bononi, A., Cavenee, W. K., Cleaver, J. E., Croce, C. M., D’Andrea, A. D., Foulkes, W. D., Gaudino, G., et al. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0265-y · Cited by 198
Mutant p53: it’s not all one and the same
Kennedy, M. C., & Lowe, S. W. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00989-y · Cited by 211
Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li–Fraumeni syndrome
Amadou, A., Achatz, M. I., & Hainaut, P. L. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000423 · Cited by 188
How I diagnose and manage individuals at risk for inherited myeloid malignancies
The University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) · Blood · doi:10.1182/blood-2016-05-670240 · Cited by 186
Gene panel testing of 5589 BRCA 1/2 ‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer
Hauke, J., Horvath, J. E., Groß, E., Gehrig, A., Honisch, E., Hackmann, K., Schmidt, G., Arnold, N., Faust, U., Sutter, C., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1376 · Cited by 177
Breast cancer prevention in high-risk women
Thorat, M. A., & Balasubramanian, R. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.11.006 · Cited by 176
Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants
Fortuño, C., Lee, K., Olivier, M., Pesaran, T. F., Mai, P. L., de Andrade, K. C., Attardi, L. D., Crowley, S. B., Evans, D. G., Feng, B., et al. (2020) · Human Mutation · doi:10.1002/humu.24152 · Cited by 173
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set
Kratz, C. P., Freyçon, C., Maxwell, K. N., Nichols, K. E., Schiffman, J. D., Evans, D. G., Achatz, M. I., Savage, S. A., Weitzel, J. N., Garber, J. E., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4398 · Cited by 148
Inhibition of p53 inhibitors: progress, challenges and perspectives
Sanz, G., Singh, M., Peuget, S., & Selivanova, G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz075 · Cited by 140
Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study
de Andrade, K. C., Khincha, P. P., Hatton, J. N., Frone, M. N., Wegman-Ostrosky, T., Mai, P. L., Best, A. F., & Savage, S. A. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00580-5 · Cited by 145
Identification, genetic testing, and management of hereditary melanoma
Leachman, S. A., Lucero, O. M., Sampson, J. E., Cassidy, P. B., Bruno, W., Queirolo, P., & Ghiorzo, P. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9661-5 · Cited by 141
Predisposition to cancer in children and adolescents
Kratz, C. P., Jongmans, M. C., Cavé, H., Wimmer, K., Behjati, S., Guerrini-Rousseau, L., Milde, T., Pajtler, K. W., Golmard, L., Gauthier-Villars, M., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30275-3 · Cited by 129
Self-citation
Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review
Farid, M., & Ngeow, J. Y. Y. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0079 · Cited by 129
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group
Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127
Somatic TP53 variants frequently confound germ-line testing results
Weitzel, J. N., Chao, E., Nehoray, B., Tongeren, L. R. V., LaDuca, H., Blazer, K. R., Slavin, T. P., Pesaran, T. F., Rybak, C., Solomon, I. B., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.196 · Cited by 132
p53 tetramerization: at the center of the dominant-negative effect of mutant p53Preprint
Gencel‐Augusto, J., & Lozano, G. (2020) · Genes & Development · doi:10.1101/gad.340976.120 · Cited by 136
Li‐Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition
Valdez, J. M., Nichols, K. E., & Kesserwan, C. A. (2016) · British Journal of Haematology · doi:10.1111/bjh.14461 · Cited by 124
Pathophysiology of Acute Myeloid Leukemia
Wachter, F., & Pikman, Y. (2024) · Acta Haematologica · doi:10.1159/000536152 · Cited by 140
Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome
Renaux‐Petel, M., Charbonnier, F., Théry, J., Fermey, P., Lienard, G., Bou, J., Coutant, S., Vézain, M., Kasper, E., Fourneaux, S., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-104976 · Cited by 124
Self-citation
Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management
Slavin, T. P., Niell‐Swiller, M., Solomon, I. B., Nehoray, B., Rybak, C., Blazer, K. R., & Weitzel, J. N. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00208 · Cited by 118
Lung cancer is also a hereditary disease
Benusiglio, P. R., Fallet, V., Sanchis-Borja, M., Coulet, F., & Cadranel, J. L. (2021) · European Respiratory Review · doi:10.1183/16000617.0045-2021 · Cited by 111
Self-citation
Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy
Schmiegelow, K., Müller, K., Mogensen, S. S., Mogensen, P. R., Wolthers, B. O., Stoltze, U. K., Tuckuviene, R., & Frandsen, T. L. (2017) · F1000Research · doi:10.12688/f1000research.10768.1 · Cited by 102
Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis
de Andrade, K. C., Frone, M. N., Wegman-Ostrosky, T., Khincha, P. P., Kim, J., Amadou, A., Santiago, K. M., Fortes, F. P., Lemonnier, N., Mirabello, L. J., et al. (2018) · Human Mutation · doi:10.1002/humu.23673 · Cited by 102
First evidence of genotype–phenotype correlations in Gorlin syndrome
Evans, D. G., Oudit, D., Smith, M. J., Rutkowski, D., Allan, E., Newman, W. G., & Lear, J. T. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-104669 · Cited by 98
Clonal hematopoiesis and risk for hematologic malignancy
Warren, J. T., & Link, D. C. (2020) · Blood · doi:10.1182/blood.2019000991 · Cited by 98
Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers
Nones, K., Johnson, J., Newell, F., Patch, A. M., Thorne, H., Kazakoff, S. H., de Luca, X. M., Parsons, M. T., Ferguson, K., Reid, L. E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz132 · Cited by 93
“WGS provided evidence regarding the drivers of tumorigenesis in many cases, including germline carriers of variants in BRCA2 (VUS), PALB2, CHEK2, ATM and TP53; BRCA1 promoter methylation, APOBEC mutagenesis and oncogene amplification.”
Influential
Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing
Rana, H. Q., Gelman, R. S., LaDuca, H., McFarland, R. E., Dalton, E., Thompson, J. D., Speare, V., Dolinsky, J. S., Chao, E., & Garber, J. E. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy001 · Cited by 96
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
Leroy, B., Ballinger, M. L., Baran‐Marszak, F., Bond, G. L., Braithwaite, A. W., Concin, N., Donehower, L. A., El‐Deiry, W. S., Fenaux, P., Gaïdano, G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2179 · Cited by 95
Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis
Batalini, F., Peacock, E. G., Stobie, L., Robertson, A., Garber, J. E., Weitzel, J. N., & Tung, N. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1193-1 · Cited by 94
Inherited TP53 Variants and Risk of Prostate Cancer
Maxwell, K. N., Cheng, H. H., Powers, J. M., Gulati, R., Ledet, E. M., Morrison, C. E., Le, A. N., Hausler, R. M., Stopfer, J. E., Hyman, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.10.036 · Cited by 95
Hematologic malignancies and Li–Fraumeni syndromePreprint
Swaminathan, M., Bannon, S. A., Routbort, M. J., Naqvi, K., Kadia, T. M., Takahashi, K., Alvarado, Y., Ravandi‐Kashani, F., Patel, K. P., Champlin, R., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003210 · Cited by 85
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 97
Hereditary breast cancer: syndromes, tumour pathology and molecular testing
Sokolova, A., Johnstone, K. J., Reed, A. E. M., Simpson, P. T., & Lakhani, S. R. (2022) · Histopathology · doi:10.1111/his.14808 · Cited by 95
Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes
Thariat, J., Chevalier, F., Orbach, D. H., Ollivier, L., Marcy, P. Y., Corradini, N., Beddok, A., Foray, N., & Bougeard, G. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00425-3 · Cited by 91
Self-citation
Twenty‐year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors
Xu, Y., Shi, F., Zhang, Y., Yin, M., Han, X., Feng, J., & Wang, G. (2023) · International Journal of Cancer · doi:10.1002/ijc.34694 · Cited by 79
Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families
Castéra, L., Harter, V., Muller, E., Krieger, S., Goardon, N., Ricou, A., Rousselin, A., Paimparay, G., Legros, A., Bruet, O., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0005-9 · Cited by 73
Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia
Bloom, M., Maciaszek, J. L., Clark, M. E., Pui, C., & Nichols, K. E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2020.1685866 · Cited by 79
An update on the central nervous system manifestations of Li–Fraumeni syndrome
Orr, B. A., Clay, M. R., Pinto, E. M., & Kesserwan, C. A. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02055-3 · Cited by 80
The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia
Rudelius, M., Weinberg, O. K., Niemeyer, C. M., Shimamura, A., & Calvo, K. R. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03447-9 · Cited by 72
Medical guidelines for Li–Fraumeni syndrome 2019, version 1.1
Kumamoto, T., Yamazaki, F., Nakano, Y., Tamura, C., Tashiro, S., Hattori, H., Nakagawara, A., & Tsunematsu, Y. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02011-w · Cited by 71
Screening for familial cancer risk: Focus on breast cancer
Rousset‐Jablonski, C., & Gompel, A. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.08.004 · Cited by 70
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls
Saya, S., Killick, E., Thomas, S. A., Taylor, N., Bancroft, E. K., Rothwell, J., Benafif, S., Dias, A., Mikropoulos, C., Pope, J., et al. (2017) · Familial Cancer · doi:10.1007/s10689-017-9965-1 · Cited by 70
The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes
Smith, M. J., Urquhart, J. E., Harkness, E. F., Miles, E. K., Bowers, N. L., Byers, H., Bulman, M. P., Gokhale, C., Wallace, A. J., Newman, W. G., et al. (2015) · Human Mutation · doi:10.1002/humu.22938 · Cited by 69
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
Wong, D., Luo, P., Oldfield, L. E., Gong, H., Brunga, L., Rabinowicz, R., Subasri, V., Chan, C. F., Downs, T., Farncombe, K. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0456 · Cited by 66
Germline mutations in young non-smoking women with lung adenocarcinoma
Donner, I., Katainen, R., Sipilä, L. J., Aavikko, M., Pukkala, ., & Aaltonen, L. A. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.027 · Cited by 65
Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity
Shahbandi, A., & Jackson, J. G. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0074-x · Cited by 65
Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: A hereditary cancer registry study
Hendrickson, P. G., Luo, Y., Kohlmann, W., Schiffman, J., Maese, L., Bishop, A. J., Lloyd, S., Kokeny, K. E., Hitchcock, Y. J., Poppe, M. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3427 · Cited by 64
The missing heritability of familial colorectal cancer
Schubert, S. A., Morreau, H. M., de Miranda, N. F. C. C., & van Wezel, T. (2019) · Mutagenesis · doi:10.1093/mutage/gez027 · Cited by 69
Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort
Mai, P. L., Khincha, P. P., Loud, J. T., DeCastro, R. M., Bremer, R. C., Peters, J. A., Liu, C., Bluemke, D. A., Malayeri, A. A., & Savage, S. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1350 · Cited by 64
Higher-than-expected population prevalence of potentially pathogenic germlineTP53variants in individuals unselected for cancer history
de Andrade, K. C., Mirabello, L. J., Stewart, D. R., Karlins, E., Koster, R., Wang, M., Gapstur, S. M., Gaudet, M. M., Freedman, N. D., Landi, M. T., et al. (2017) · Human Mutation · doi:10.1002/humu.23320 · Cited by 63
Specific regulation of BACH1 by the hotspot mutant p53R175H reveals a distinct gain-of-function mechanism
Su, Z., Kon, N., Yi, J., Zhao, H., Zhang, W., Tang, Q., Li, H., Kobayashi, H. H., Li, Z., Duan, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00532-z · Cited by 64
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome
Le, A. N., Harton, J. G., Desai, H., Powers, J. M., Zelley, K., Bradbury, A. R., Nathanson, K. L., Shah, P. D., Doucette, A. G., Freedman, G. M., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05612-7 · Cited by 62
STAT3 and p53: Dual Target for Cancer Therapy
Pham, T., Park, H., Kim, J., Hong, J. T., & Yoon, D. (2020) · Biomedicines · doi:10.3390/biomedicines8120637 · Cited by 63
Current and Emerging Roles of Whole-Body MRI in Evaluation of Pediatric Cancer Patients
Gottumukkala, R. V., Gee, M. S., Hampilos, P. J., & Greer, M. C. (2019) · Radiographics · doi:10.1148/rg.2019180130 · Cited by 61
The spectrum of mutations predisposing to familial breast cancer in Poland
Cybulski, C., Kluźniak, W., Huzarski, T., Wokołorczyk, D., Kashyap, A., Rusak, B., Stempa, K., Gronwald, J., Szymiczek, A., Bagherzadeh, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32492 · Cited by 62
UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
Hanson, H., Brady, A. F., Crawford, G., Eeles, R. A., Gibson, S., Jørgensen, M., Izatt, L., Sohaib, A., Tischkowitz, M. D., & Evans, D. G. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-106876 · Cited by 58
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome
Mezquita, L., Jové, M., Nadal, E., Kfoury, M., Morán, T., Ricordel, C., Dhooge, M., Tlemsani, C., Léna, H., Teulé, À., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.005 · Cited by 58
Self-citation
Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations
Kasper, E., Angot, É., Colasse, É., Nicol, L., Sabourin, J., Adriouch, S., Lacoume, Y., Charbonnier, C., Raad, S., Frébourg, T., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.011 · Cited by 57
Self-citation
Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?
McBride, K. A., Ballinger, M. L., Schlub, T. E., Young, M., Tattersall, M. H. N., Kirk, J., Eeles, R. A., Killick, E., Walker, L. G., Shanley, S., et al. (2017) · Familial Cancer · doi:10.1007/s10689-016-9964-7 · Cited by 58
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
Dutta, S., Pregartner, G., Rücker, F. G., Heitzer, E., Zebisch, A., Bullinger, L., Berghold, A., Döhner, K., & Sill, H. (2020) · Cancers · doi:10.3390/cancers12030637 · Cited by 60
A Comprehensive Review of Ovarian Serous Carcinoma
Hatano, Y., Hatano, K., Tamada, M., Morishige, K.-I., Tomita, H., Yanai, H., & Hara, A. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000243 · Cited by 56
Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era
Carta, R., Baldo, G. D., Miele, E., Pò, A., Besharat, Z. M., Nazio, F., Colafati, G. S., Piccirilli, E., Agolini, E., Rinelli, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566822 · Cited by 60
Mutant p53 in cell-cell interactionsPreprint
Pilley, S. E., Rodríguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 54
Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia—A Nationwide Register-Based Cohort Study in Germany
Dutzmann, C. M., Spix, C., Popp, I., Kaiser, M., Erdmann, F., Erlacher, M., Dörk, T., Schindler, D., Kalb, R., & Kratz, C. P. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01495 · Cited by 55
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer
Singhal, D., Hahn, C. N., Feurstein, S. K., Wee, L. Y. A., Moma, L., Kutyna, M., Chhetri, R., Eshraghi, L., SCHREIBER, A. W., Feng, J., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01246-w · Cited by 54
Li–Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53
Zhou, R., Xu, A., Gingold, J. A., Strong, L. C., Zhao, R., & Lee, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.004 · Cited by 52
Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic
Bojadzieva, J., Amini, B., Day, S., Jackson, T. L., Thomas, P. S., Willis, B. J., Throckmorton, W., Daw, N. C., Bevers, T. B., & Strong, L. C. (2017) · Familial Cancer · doi:10.1007/s10689-017-0034-6 · Cited by 52
Retroperitoneal Sarcoma Care in 2021
Schmitz, E. M., & Nessim, C. (2022) · Cancers · doi:10.3390/cancers14051293 · Cited by 52
Historical Perspective on Familial Gastric Cancer
Boland, C. R., & Yurgelun, M. B. B. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.12.003 · Cited by 51
Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial
Bailey, S., André, N., Gandola, L., Massimino, M., Wheatley, K., Gates, S., Homer, V., Rutkowski, S., & Clifford, S. C. (2022) · Cancers · doi:10.3390/cancers14020374 · Cited by 51
Heritable defects in telomere and mitotic function selectively predispose to sarcomas
Ballinger, M. L., Pattnaik, S., Mundra, P. A., Zaheed, M., Rath, E. M., Priestley, P., Baber, J., Ray-Coquard, I. L., Isambert, N., Causeret, S., et al. (2023) · Science · doi:10.1126/science.abj4784 · Cited by 49
Update on Cancer Screening Recommendations for Individuals with Li–Fraumeni Syndrome
Achatz, M. I., Villani, A., Bertuch, A. A., Bougeard, G., Chang, V. Y., Doria, A. S., Gallinger, B., Godley, L. A., Greer, M. C., Kamihara, J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3301 · Cited by 49
Self-citation
Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage
Zerdoumi, Y., Lanos, R., Raad, S., Flaman, J., Bougeard, G., Frébourg, T., & Tournier, I. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx106 · Cited by 52
Self-citation
Acute myeloid leukemia with TP53 germ line mutations
Zebisch, A., Lal, R., Müller, M., LIND, K., Kashofer, K., Girschikofsky, M., Fuchs, D., Wölfler, A., Geigl, J. B., & Sill, H. (2016) · Blood · doi:10.1182/blood-2016-08-732610 · Cited by 51
Hereditary myeloid malignancies
Rafei, H., & Dinardo, C. D. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.001 · Cited by 49
DNA methylation signature is prognostic of choroid plexus tumor aggressiveness
Pieńkowska, M., Choufani, S., Turinsky, A. L., Guha, T., Merino, D. M., Novokmet, A., Brudno, M., Weksberg, R., Shlien, A., Hawkins, C. E., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0708-z · Cited by 48
Familial and hereditary gastric cancer, an overview
Carneiro, F. (2022) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2022.101800 · Cited by 47
Germline TP53 pathogenic variants and breast cancer: A narrative review
Blondeaux, E., Arecco, L., Punie, K., Graffeo, R., Toss, A., Angelis, C. D., Trevisan, L., Buzzatti, G., Linn, S. C., Dubsky, P. C., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102522 · Cited by 55
Li–Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment
Rocca, V., Blandino, G., D’Antona, L., Iuliano, R., & Agostino, S. D. (2022) · Cancers · doi:10.3390/cancers14153664 · Cited by 50
Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes
Michaeli, O., & Tabori, U. Y. (2018) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2018.0031 · Cited by 46
Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome
Fortuño, C., James, P. A., & Spurdle, A. B. (2018) · Human Mutation · doi:10.1002/humu.23656 · Cited by 46
Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis
Light, N. D., Layeghifard, M., Attery, A., Subasri, V., Zatzman, M., Anderson, N. D., Hatkar, R., Blay, S., Chen, D. D., Novokmet, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35727-y · Cited by 47
Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53
Lolas, S., Renbaum, P., Kamal, L., Dweik, D., Salahat, M., Jarayseh, T., Rayyan, A. A., Casadei, S., Mandell, J. B., Gülsüner, S., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30771 · Cited by 44
Germline mutations predisposing to diffuse large B-cell lymphoma
Leeksma, O. C., de Miranda, N. F. C. C., & Veelken, H. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.15 · Cited by 44
Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients
Ceyhan‐Birsoy, O., Jayakumaran, G., Kemel, Y. M., Misyura, M., Aypar, U., Jairam, S., Yang, C., Li, Y., Mehta, N. N., Maio, A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01101-2 · Cited by 47
Li-Fraumeni Syndrome and Whole-Body MRI Screening: Screening Guidelines, Imaging Features, and Impact on Patient Management
Consul, N., Amini, B., Ibarra-Rovira, J. J., Blair, K. J., Moseley, T. W., Taher, A., Shah, K. B., & Elsayes, K. M. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.20.23008 · Cited by 42
Germline genetic landscape of pediatric central nervous system tumors
Muskens, I. S., Zhang, C., de Smith, A. J., Biegel, J. A., Walsh, K. M., & Wiemels, J. L. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz108 · Cited by 41

Authors: Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., Caron, O., Benusiglio, P. R., Bressac-de Paillerets, B., Bonadona, V., Bonaïti-Pellié, C., Tinat, J., Baert-Desurmont, S., & Frebourg, T.
Affiliations: Inserm (FR)
Gaëlle Bougeard, Mariette Renaux-Petel, Jean-Michel Flaman, Camille Charbonnier, Pierre Fermey, Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, Institut National de la Santé et de la Recherche Médicale (Inserm) U1079, University of Rouen, Institute for Research and Innovation in Biomedicine; Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, University Hospital, Rouen; Muriel Belotti, Marion Gauthier-Villars, Dominique Stoppa-Lyonnet, Curie Institute, Paris; Emilie Consolino, Laurence...
ORCID: Bougeard, Gaëlle
Flaman, Jean-Michel
Charbonnier, Camille
Brugières, Laurence
Caron, Olivier
Benusiglio, Patrick R.
Bonadona, Valérie
Tinat, Julie
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-07-20
Volume: 33
Issue: 21
Pages: 2345-2352
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.5728
OpenAlex: W2095770043
Cited by: 760
References: 42
Citations by year: 2026: 68 · 2025: 85 · 2024: 95 · 2023: 67 · 2022: 82 · 2021: 81 · 2020: 78 · 2019: 59 · 2018: 42 · 2017: 64 · 2016: 30 · 2015: 9
FWCI: 21.11
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: Li-Fraumeni syndrome, germline TP53 mutation, cancer susceptibility, multiple primary neoplasms, childhood tumors, osteosarcoma, adrenocortical carcinoma, choroid plexus carcinoma, breast cancer, soft tissue sarcoma, central nervous system tumors, loss-of-function mutations, genome rearrangement, mutation classification
MeSH terms: Adolescent, Adult, Female, France, Genetic Testing, Genotype, Humans, Male, Phenotype, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Sequence Analysis, DNA, Age of Onset, Germ-Line Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks